Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunology

Set Alert for Immunology

Biotechs Vie To Take The Lead In Autoimmune CAR-Ts

First clinical efficacy readouts from several biotech companies developing CAR-Ts for systemic lupus erythematosus will be unveiled at EULAR, though the level of competition may be unsustainable.

Clinical Trials Companies

InflaRx Undaunted By Dermatology Rivals

The group says INF904 can make billions in two highly competitive skin diseases, but this looks optimistic.

Clinical Trials Commercial

Amgen Phase III Data Could Add Second Indication To Uplizna’s Label

Amgen’s study shows an 87% risk-reduction for IgG4-related disease flares, which can exacerbate the rare disorder and lead to irreversible organ failure. A US filing is planned.

Clinical Trials Rare Diseases

Early Results Erode Belief In Biohaven’s Protein Degrader

Phase I results from BHV-1300 underwhelmed investors, but Biohaven is moving ahead and has many more shots on goal in protein degradation and beyond.

Clinical Trials Companies

J&J Continues Atopic Dermatitis Effort With Numab Deal

Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.

M & A Business Strategies

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Biogen’s immunology acquisition; AstraZeneca looks to cement respiratory lead; why US FTC is tough on pharma; the US election’s impact on pharma; and how new AI tools are impacting medical affairs. 

M & A Commercial

First-To-Market Calliditas Picking Up Speed In IgA Nephropathy

A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.

Sales & Earnings Companies

Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal

Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab. 

Deals M & A

Amgen/AstraZeneca’s Tezspire Shows Efficacy In Broader COPD Population

Anti-TSLP antibody Tezspire (tezepelumab) showed efficacy in a Phase IIa study versus placebo in COPD patients with lower eosinophil levels than those tested in Dupixent’s pivotal studies.

Clinical Trials Respiratory

Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

Financing Immune Disorders

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.

Financing Immune Disorders

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.

Immune Disorders Inflammation
See All
UsernamePublicRestriction

Register